Disease-related modifications in tau affect the interaction between Fyn and tau

被引:190
作者
Bhaskar, K
Yen, SH
Lee, G
机构
[1] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA
[2] Mayo Clin Jacksonville, Dept Neurosci, Jacksonville, FL 32224 USA
关键词
D O I
10.1074/jbc.M505895200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Microtubule-associated protein tau is the major component of the neurofibrillary tangles of Alzheimer disease (AD) and is genetically linked to frontotemporal dementias (FTDP-17). We have recently shown that tau interacts with the SH3 domain of Fyn, an Src family non-receptor tyrosine kinase, and is tyrosine-phosphorylated by Fyn on Tyr-18. Also, tyrosine-phosphorylated tau is present in the neuropathology of AD. To determine whether alterations in the tau-Fyn interaction might correlate with disease-related factors in AD and FTDP-17, we have performed real-time surface plasmon resonance studies on a panel of 21 tau constructs with Fyn SH3. We report that the interaction between Fyn SH3 and 3R-tau was 20-fold higher than that with 4R-tau. In addition, the affinity between 4R-tau and Fyn SH3 was increased 25-45-fold by phosphorylation-mimicking mutations or by FTDP-17 mutations. In vitro kinase reactions show that tau, with lower affinity SH3 interactions, exhibited a lower level of Tyr-18 phosphorylation under our reaction conditions. Lastly, we have demonstrated that tau is phosphorylated on Tyr-18 in the tau P301L mouse model for tauopathy (JNPL3). In summary, our results suggest that disease-related phosphorylation and missense mutations of tau increase association of tau with Fyn. Because these effects are mediated through the 4R component of the tau population, these results also have implications for the FTDP-17 diseases caused by increased expression of 4R-tau. Our data support a role for the Fyn-tau interaction in neurodegeneration.
引用
收藏
页码:35119 / 35125
页数:7
相关论文
共 43 条
[21]  
Hutton M, 2000, ANN NY ACAD SCI, V920, P63
[22]   Tau pathology in Alzheimer disease and other tauopathies [J].
Iqbal, K ;
Alonso, ADC ;
Chen, S ;
Chohan, MO ;
El-Akkad, E ;
Gong, CX ;
Khatoon, S ;
Li, B ;
Liu, F ;
Rahman, A ;
Tanimukai, H ;
Grundke-Iqbal, I .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2005, 1739 (2-3) :198-210
[23]  
Jicha GA, 1997, J NEUROCHEM, V69, P2087
[24]   The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains [J].
Kay, BK ;
Williamson, MP ;
Sudol, P .
FASEB JOURNAL, 2000, 14 (02) :231-241
[25]   Pathways of tau fibrillization [J].
Kuret, J ;
Chirita, CN ;
Congdon, EE ;
Kannanayakal, T ;
Li, GB ;
Necula, M ;
Yin, HS ;
Zhong, Q .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2005, 1739 (2-3) :167-178
[26]   Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins [J].
Lambert, MP ;
Barlow, AK ;
Chromy, BA ;
Edwards, C ;
Freed, R ;
Liosatos, M ;
Morgan, TE ;
Rozovsky, I ;
Trommer, B ;
Viola, KL ;
Wals, P ;
Zhang, C ;
Finch, CE ;
Krafft, GA ;
Klein, WL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (11) :6448-6453
[27]  
Lee G, 1998, J CELL SCI, V111, P3167
[28]   Phosphorylation of tau by fyn: Implications for Alzheimer's disease [J].
Lee, G ;
Thangavel, R ;
Sharma, VM ;
Litersky, JM ;
Bhaskar, K ;
Fang, SM ;
Do, LH ;
Andreadis, A ;
Van Hoesen, G ;
Ksiezak-Reding, H .
JOURNAL OF NEUROSCIENCE, 2004, 24 (09) :2304-2312
[29]   Neurodegenerative tauopathies [J].
Lee, VMY ;
Goedert, M ;
Trojanowski, JQ .
ANNUAL REVIEW OF NEUROSCIENCE, 2001, 24 :1121-1159
[30]   Insulin transiently increases tau phosphorylation:: Involvement of glycogen synthase kinase-3β and Fyn tyrosine kinase [J].
Lesort, M ;
Jope, RS ;
Johnson, GVW .
JOURNAL OF NEUROCHEMISTRY, 1999, 72 (02) :576-584